文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌每日在线自适应放疗与传统IGRT的患者报告结局前瞻性对照研究

Prospective controlled study comparing patient-reported outcomes after daily online adaptive radiotherapy or conventional IGRT in patients with prostate cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-12-05

oART组在高危患者更多(40.5% vs 9.7%,p=0.03)的情况下,HRQoL各领域下降呈较小趋势但多未达统计学显著,NCI-PRO-CTCAE显示oART组尿急和粪失禁评分更优(p=0.02)。

要点

  • oART组EPIC泌尿功能下降-9.53 vs IGRT组-17.47,p=0.05,趋势 favoring oART但未显著。
  • NCI-PRO-CTCAE尿急(0.95 vs 1.57)和粪失禁(0.03 vs 0.71)oART组显著更优,p=0.02。
  • oART组达到MCID泌尿和肠道恶化阈值的患者比例较少,但差异无统计学意义。

核心结论

  • 结果提示oART相比传统IGRT在PROM评分上有小幅但一致的有利趋势。
  • 该结果可为未来随机对照试验设计提供参考。

研究设计与样本

  • 两组均接受62 Gy/20次放疗,分别采用每日CBCT在线自适应放疗或CBCT引导传统IGRT。
  • PROMs(EPIC、QLQ-PR25、IPSS、NCI-PRO-CTCAE)在基线和治疗结束时采集,分析评分变化及基于MCID的临床意义恶化。

主要发现

  • oART组高危肿瘤患者比例高于IGRT组(40.5% vs 9.7%,p=0.03),其余人口学特征相似。
  • EPIC泌尿摘要评分变化-12.15 vs -20.57(p=0.07),泌尿功能-9.53 vs -17.47(p=0.05),尿失禁-5.47 vs -13.93(p=0.07),PR25泌尿症状20.0 vs 27.5(p=0.06)。
  • EPIC肠道功能下降-12.64 vs -19.78(p=0.10)。
  • NCI-PRO-CTCAE尿急评分0.95 vs 1.57(p=0.02),粪失禁0.03 vs 0.71(p=0.02),均 favoring oART。
  • oART组达到MCID泌尿(8-21%)和肠道(20-23%)恶化阈值的患者较少,但差异无统计学意义。

关键数值与推荐

  • oART组EPIC泌尿摘要评分变化-12.15,IGRT组-20.57,p=0.07。
  • oART组EPIC泌尿功能变化-9.53,IGRT组-17.47,p=0.05。
  • oART组NCI-PRO-CTCAE尿急评分0.95,IGRT组1.57,p=0.02。
  • oART组NCI-PRO-CTCAE粪失禁评分0.03,IGRT组0.71,p=0.02。

临床怎么用

  • 对于局限期前列腺癌行62 Gy/20次大分割放疗,oART可能减轻患者报告的泌尿和肠道症状恶化。
  • oART组在高危患者比例更高的情况下仍显示PROM有利趋势,支持进一步随机对照验证。

局限性

  • 采用便利分配而非随机分组,可能存在选择偏倚。
  • oART组高危肿瘤患者比例显著高于IGRT组(40.5% vs 9.7%,p=0.03),组间基线风险不均衡。
  • PROM仅在基线和治疗结束时采集,缺乏治疗后长期随访数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare patient-reported outcome measures (PROMs) in patients treated either with cone-beam CT (CBCT)-based online adaptive radiotherapy (oART) or with CBCT-guided conventional image guided radiotherapy (IGRT). MATERIALS AND METHODS: In this prospective study with convenience allocation, patients with localized prostate cancer received 62 Gy/20 fractions using either daily CBCT-based oART or CBCT-guided conventional IGRT. PROMs (EPIC, QLQ-PR25, IPSS, NCI-PRO-CTCAE) were collected at baseline and at end of therapy. Changes in scores and clinically meaningful deterioration, based on established minimal clinically important differences (MCID), were analyzed. RESULTS: Seventy-four patients were included (oART: 58.1 %; IGRT: 41.9 %). Groups were demographically similar, although the oART group included more patients with high-risk tumors (40.5 % vs. 9.7 %, p = 0.03). Patients after oART tended to experience smaller, although not statistically significant, declines in health-related quality of life (HRQoL) domains compared to IGRT: EPIC urinary summary (-12.15 vs -20.57, p = 0.07), urinary function (-9.53 vs -17.47, p = 0.05), urinary incontinence (-5.47 vs -13.93, p = 0.07) and PR25 urinary symptom (20.0 vs. 27.5, p = 0.06). EPIC bowel function decline was also less pronounced (-12.64 vs. -19.78, p = 0.10). NCI-PRO-CTCAE scores favored oART for reduced urinary urgency (0.95 vs. 1.57, p = 0.02) and fecal incontinence (0.03 vs. 0.71, p = 0.02). Fewer oART patients reached MCID thresholds for urinary (8-21 %) and bowel (20-23 %) deterioration, but these differences were not statistically significant. CONCLUSION: Our results suggest a small but consistent trend in PROM scores favoring oART over conventional IGRT. In addition, the results may inform the design of controlled randomized trials in the future.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kalinauskaite G, Künzel LA, Rubarth K, et al. Prospective controlled study comparing patient-reported outcomes after daily online adaptive radiotherapy or conventional IGRT in patients with prostate cancer. Clin Transl Radiat Oncol. 2025. PMID: 41492405. doi:10.1016/j.ctro.2025.101092

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。